Company Overview
Company Type: Public Company
Website: www.pivotaltherapeutics.us
Number of Employees: -
Ticker: PVTT.F (OTCPK)
Year Founded: -


Business Description
Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.4
Market Capitalization
0.2
EBITDA
(3.1)
EBIT
(3.2)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(3.7)
Total Debt
7.0
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
1.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Sep-30-2015 TEV and Market Cap are calculated using a close price as of Mar-23-2023

Key Professionals
Name
Title
MacSweeney, Rachelle 
Co-Founder, CEO, President & Director
Jackowski, George 
Co-Founder, Chief Scientific Officer & Director

Key Board Members
Name
Title
Gebhardt, John S.
Independent Non-Executive Chairman
MacSweeney, Rachelle 
Co-Founder, CEO, President & Director
Jackowski, George 
Co-Founder, Chief Scientific Officer & Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
81 Zenway Boulevard Unit 10 | Woodbridge, ON | L4H 0S5 | Canada
Phone: 905-856-9797   Fax: 905-856-2177

Current and Pending Investors
Broadfin Capital, LLC, Porter Capital Management Co., Summer Street Research Partners, Asset Management Arm


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Media Script Marketing Inc.
As of April 7, 2011, Media Script Marketing Inc. was acquired by Pivotal Therapeutics Inc. Media Script Marketing Inc. was incorporated in 2010 and is based in Vancouver, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
Pivotal Therapeutics (us), Inc.
Pivotal Therapeutics (us), Inc. operates as a pharmaceuticals company. It is headquartered in Boca Raton, Florida.

United States and Canada
Pharmaceuticals
1.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-05-2015
Nov-27-2015
Private Placement
Target
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)


0.07
Jun-29-2015
Cancelled
Private Placement
Target
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)


1.17
Oct-2-2013
Mar-4-2014
Private Placement
Target
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
Summer Street Research Partners, Asset Management Arm,Broadfin Capital, LLC,Porter Capital Management Co. Buyer Funds:Crossover Healthcare Fund, LLC

6.97
Jun-24-2012
Oct-02-2013
Private Placement
Target
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
Summer Street Research Partners, Asset Management Arm Buyer Funds:Crossover Healthcare Fund, LLC

2.65
Feb-3-2011
Apr-7-2011
Merger/Acquisition
Buyer
Media Script Marketing Inc.
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-23-2017
Delistings
Pivotal Therapeutics To Be Delisted From Canadian Securities Exchange
Dec-01-2016
Lawsuits & Legal Issues
Pivotal Therapeutics Inc. Receives Statement of Claim and Files Statement of Defence and - Counterclaim against Crossover Healthcare Fund, LLC
May-06-2016
Executive/Board Changes - Other, Executive Changes - CEO, Executive Changes - CFO
Pivotal Therapeutics Inc. Announces Management Changes
Dec-15-2015
Client Announcements
Ford Teams with Pivotal to Speed Development of Connected Car Experiences Capitalizing on New Ford Sync Connect
Nov-30-2015
Announcements of Earnings
Pivotal Therapeutics Inc. Announces Earnings Results for the Nine Months Ended September 30, 2015


Advisors
Most Recent Auditor
MNP LLP
Private Placement Advisors
Custom Equity Research Partners LLC


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 25, 2023 02:12 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Jun 23, 2023 05:51 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Mar 27, 2023 03:33 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Dec 22, 2022 02:29 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Sep 19, 2022 08:45 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Jun 22, 2022 04:49 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Mar 23, 2022 03:37 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
79
GlobalData

Dec 14, 2021 01:28 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
22
GlobalData

Sep 15, 2021 04:50 AM
PVTT.F
Pivotal Therapeutics Inc
Reports
15
GlobalData

Jun 15, 2021 08:21 PM
PVTT.F
Pivotal Therapeutics Inc
Reports
15



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Fisher Asset Management, LLC
0
(15,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Benefishial, Lovaza, OMAZEN, OmegaSTAT (Future), PVT-100 (Future), VASCAZEN


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
May-06-2016
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
21 KB
Nov-30-2015
Sep-30-2015
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
Interim Financial Statements
753 KB
Nov-20-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
530 KB
Nov-20-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
499 KB
Nov-05-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
499 KB
Oct-08-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
514 KB
Sep-28-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
503 KB
Sep-22-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
535 KB
Aug-31-2015
-
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
News Releases
529 KB
Aug-28-2015
Jun-30-2015
Pivotal Therapeutics Inc. (OTCPK:PVTT.F)
SEDAR
Interim Financial Statements
760 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Summer Street Research Partners, Asset Management Arm
Oct-13-2015 - Oct-14-2015
New Common Shares
57,000
2,878
Open Market Acquisition
0.42
Exchange Announcement
-
Oct-13-2015
New Common Shares
46,000
2,298
Open Market Acquisition
-
Exchange Announcement
-
Oct-14-2015
New Common Shares
11,000
579
Open Market Acquisition
-
Exchange Announcement
Summer Street Research Partners, Asset Management Arm
Jun-17-2015
New Common Shares
166,284
11,092
Other Acquisition
1.23
Exchange Announcement
Summer Street Research Partners, Asset Management Arm
Dec-18-2014 - Dec-19-2014
New Common Shares
34,000
2,604
Open Market Acquisition
0.26
Exchange Announcement
-
Dec-18-2014
New Common Shares
25,000
1,915
Open Market Acquisition
-
Exchange Announcement
-
Dec-19-2014
New Common Shares
9,000
689
Open Market Acquisition
-
Exchange Announcement
Summer Street Research Partners, Asset Management Arm
Dec-17-2014
New Common Shares
164,476
-
Other Acquisition
1.23
Exchange Announcement
Summer Street Research Partners, Asset Management Arm
Dec-15-2014
New Common Shares
40,000
3,059
Open Market Acquisition
0.30
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Gebhardt, John S.
Independent Non-Executive Chairman
905-856-9797
905-856-2177

MacSweeney, Rachelle 
Co-Founder, CEO, President & Director
905-856-9797
905-856-2177
rmacsweeney@pivotaltherapeutics.us
Jackowski, George 
Co-Founder, Chief Scientific Officer & Director
905-856-9797
905-856-2177

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
MacSweeney, Rachelle 
Co-Founder, CEO, President & Director
905-856-9797
905-856-2177
rmacsweeney@pivotaltherapeutics.us
Jackowski, George 
Co-Founder, Chief Scientific Officer & Director
905-856-9797
905-856-2177

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
